Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | MYC | P01106 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.38 |
| ▸ | XIAP | P98170 | 2/20 | 0.38 |
| ▸ | BIRC2 | Q13490 | 2/20 | 0.38 |
| ▸ | SMO | Q99835 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | GHSR | Q92847 | 2/20 | 0.37 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4805051 | 1.00 | HTT (0.45) | HTTHTR6MYCL3MBTL1NOTUM | |
| SCHEMBL27698181 | 0.85 | HTT (0.42) | HTTHTR6MYCL3MBTL1NOTUM | |
| SCHEMBL13176039 | 0.80 | CCR2 (0.41) | MYCNOTUMDRD4HCRTR1HCRTR2 | |
| SCHEMBL8259624 | 0.78 | MAPT (0.49) | HTTL3MBTL1NOTUMDRD4 | |
| SCHEMBL4933476 | 0.75 | HTT (0.51) | HTTHTR6L3MBTL1NOTUMDRD4 | |
| SCHEMBL4933480 | 0.75 | HTT (0.51) | HTTHTR6L3MBTL1NOTUMDRD4 | |
| SCHEMBL4799688 | 0.71 | GHSR (0.45) | GHSR | |
| SCHEMBL4799698 | 0.71 | GHSR (0.45) | GHSR | |
| SCHEMBL16846510 | 0.68 | HCRTR2 (0.50) | MYCNOTUMHCRTR1HCRTR2 | |
| SCHEMBL4802299 | 0.68 | MAPT (0.49) | HTTL3MBTL1GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7381728-B2 | Piperazine derivatives useful for the treatment of gastrointestinal disorders | GLAXO GROUP LIMITED (GB) | 2008-06-03 | — | — | US | disclosed |
| US-20070259877-A1 | Piperazine Derivatives Useful for the Treatment of Gastrointestinal Disorders | GLAXO GROUP LIMITED | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259877-A1 | Piperazine Derivatives Useful for the Treatment of Gastrointestinal Disorders | GHSR, GHRHR, GIPR | HTT 1562/4885HTR6 313/4885MYC 2284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.